Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness

Guest Editor:

Dr. Emeric Limagne
Cancer Biology Transfer Platform, Department of Pathology and Tumor Biology, Anticancer Center Georges-François Leclerc, Dijon, France "Cancer and adaptive immune response" team, INSERM Research Center LNC-UMR1231, University of Bourgogne-Franche-Comté, Dijon, France

Deadline for manuscript submissions:
closed (30 June 2021)

Message from the Guest Editor

Inhibitory antibodies targeting the PD-1/PD-L1 pathway are now widely used in different types of cancers such as melanoma, lung, head and neck, kidney, and some hematological malignancies. The medical advances made possible by these new drugs are undeniable, however, a significant number of patients do not benefit from this therapy due to the intrinsic or acquired resistance of their tumor to PD-(L)1 inhibition.

The objective of this Special Issue entitled "Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness" is to highlight original research related to the identification of synergistic therapeutic combinations with anti-PD-(L)1 that take into account the tumor immune context. Studies that describe strategies to sensitize "cold" (immunogenic drugs, vaccination, PRR agonists) and "immuno-excluded" tumors (modulators of fibrosis, angiogenesis, etc.), or a strategy to bypass acquired resistance in previously sensitive tumors are particularly appreciated.

mdpi.com/si/44486

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us